Practice Test Geeks(BC ADM) Advanced Diabetes Management Certification Practice Test
← All BC ADM Flashcard Decks

Technology in Diabetes Flashcards

7 cards from real BC ADM practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Technology in Diabetes flashcards as text

  1. A closed-loop system increases basal insulin delivery yet the patient's postprandial glucose rises to 280 mg/dL consistently. The MOST likely explanation is:

    Answer: The patient is not pre-bolusing for meals

    Closed-loop systems optimize basal insulin but rely on patient-entered meal boluses; skipping pre-bolus causes postprandial spikes the algorithm cannot fully correct in real time.

  2. Which factor MOST significantly impairs CGM accuracy during rapid glucose changes?

    Answer: Physiological lag between interstitial and blood glucose

    Interstitial glucose lags behind blood glucose by approximately 5–10 minutes, causing CGM readings to underestimate or overestimate during rapid changes.

  3. What does a coefficient of variation (CV) >36% on a patient's CGM report indicate?

    Answer: High glycemic variability requiring management

    A CV >36% reflects high glycemic variability, which is associated with increased hypoglycemia risk and poor metabolic control independent of mean glucose.

  4. A patient with type 2 diabetes on basal insulin is considering a connected insulin pen. Which benefit is MOST relevant to their diabetes management?

    Answer: Dose logging and reminders to reduce missed or duplicate injections

    Connected insulin pens record dose timing and amount, helping patients and clinicians identify missed or duplicate injections that drive glucose variability.

  5. According to the AGP (Ambulatory Glucose Profile) report, which metric best reflects overnight hypoglycemia burden?

    Answer: Time below range <54 mg/dL (Level 2 low)

    Time below range <54 mg/dL (Level 2 hypoglycemia) is the metric most directly reflecting serious hypoglycemia burden, with a target of <1%.

  6. Which CGM site is FDA-approved for the Dexcom G6 sensor placement?

    Answer: Abdomen and back of upper arm

    The Dexcom G6 is FDA-approved for placement on the abdomen (adults) and the back of the upper arm (ages 2–17).

  7. A patient using an insulin pump develops unexplained hyperglycemia. After ruling out illness, the FIRST troubleshooting step should be:

    Answer: Administer a correction dose via syringe and change the infusion site

    Infusion site occlusion or failure is the most common pump-related cause of unexplained hyperglycemia; correcting by syringe and changing the site addresses both diagnosis and treatment.